Markus Cappel Net Worth

The estimated Net Worth of Markus J. Cappel is at least 7.27 百万$ dollars as of 4 August 2022. Markus Cappel owns over 7,564 units of ChemoCentryx Inc stock worth over 4,557,339$ and over the last 13 years he sold CCXI stock worth over 1,440,792$. In addition, he makes 1,271,680$ as Chief Business Officer、 Treasurer at ChemoCentryx Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Markus Cappel CCXI stock SEC Form 4 insiders trading

Markus has made over 56 trades of the ChemoCentryx Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he sold 7,564 units of CCXI stock worth 379,864$ on 4 August 2022.

The largest trade he's ever made was exercising 330,524 units of ChemoCentryx Inc stock on 26 November 2016 worth over 3,754,753$. On average, Markus trades about 20,445 units every 52 days since 2012. As of 4 August 2022 he still owns at least 87,658 units of ChemoCentryx Inc stock.

You can see the complete history of Markus Cappel stock trades at the bottom of the page.

Markus Cappel biography

Dr. Markus J. Cappel Ph.D. serves as Chief Business Officer, Treasurer of the Company. From March 2003 to February 2007, he served as our Senior Vice President of Corporate and Business Development. From October 2001 to March 2003, Dr. Cappel served as our Vice President of Business Development. Prior to joining us, Dr. Cappel served as Vice President of Business Development at Alkermes, Inc., a biotechnology company, from 1998 to 2001. Prior to this, he served as Director of Business Development with Millennium Pharmaceuticals as well as in various business development roles at Cygnus, Inc., a biotechnology company. Dr. Cappel received his B.S. in pharmacy and his Ph.D. in pharmaceutics from J.W. Goethe University, Frankfurt, Germany, and his M.B.A. from Harvard Business School. Dr. Cappel also completed postdoctoral studies in pharmaceutics at the University of Michigan.

What is the salary of Markus Cappel?

As the Chief Business Officer、 Treasurer of ChemoCentryx Inc, the total compensation of Markus Cappel at ChemoCentryx Inc is 1,271,680$. There are 2 executives at ChemoCentryx Inc getting paid more, with Thomas Schall having the highest compensation of 3,341,860$.

How old is Markus Cappel?

Markus Cappel is 59, he's been the Chief Business Officer、 Treasurer of ChemoCentryx Inc since 2007. There are 7 older and 6 younger executives at ChemoCentryx Inc. The oldest executive at ChemoCentryx Inc is Henry McKinnell, 77, who is the Independent Director.

What's Markus Cappel's mailing address?

Markus's mailing address filed with the SEC is C/O CHEMOCENTRYX, INC., 835 INDUSTRIAL ROAD, SUITE 600, SAN CARLOS, CA, 94070.

Insiders trading at ChemoCentryx Inc

Over the last 13 years, insiders at ChemoCentryx Inc have traded over 355,980,520$ worth of ChemoCentryx Inc stock and bought 3,166,975 units worth 19,475,662$ . The most active insiders traders include Plc Gsk、Rishi Gupta、(International) Ltd Vifor P.... On average, ChemoCentryx Inc executives and independent directors trade stock every 12 days with the average trade being worth of 4,175,785$. The most recent stock trade was executed by Susan M Kanaya on 16 August 2022, trading 19,898 units of CCXI stock currently worth 216,092$.

What does ChemoCentryx Inc do?

ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. ChemoCentryx's lead drug candidate, avacopan (CCX168), successfully completed a pivotal Phase III trial in ANCA-associated vasculitis and a New Drug Application is under review by the U.S. Food and Drug Administration. Avacopan is also in late stage clinical development for the treatment of severe Hidradenitis Suppurativa and C3 glomerulopathy (C3G). ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.

Complete history of Markus Cappel stock trades at ChemoCentryx Inc

ChemoCentryx Inc executives and stock owners

ChemoCentryx Inc executives and other stock owners filed with the SEC include:

• Thomas Schall,
  Chairman of the Board, President, Chief Executive Officer
• Susan Kanaya,
  Chief Financial Officer, Executive Vice President, Chief Administrative Officer, Secretary
• Markus Cappel,
  Chief Business Officer, Treasurer
• Dr. Thomas J. Schall Ph.D.,
  Founder, Pres, CEO & Chairman
• Susan M. Kanaya,
  Exec. VP, Chief Financial & Admin. Officer, Sec. and Director
• Dr. Markus J. Cappel Ph.D.,
  Sr. VP, Chief Bus. Officer & Treasurer
• Rita Jain,
  Independent Director
• James Tyree,
  Independent Director
• Henry McKinnell,
  Independent Director
• Thomas Edwards,
  Independent Director
• Joseph Feczko,
  Independent Director
• Geoffrey Parker,
  Independent Director
• Dr. Rita I. Jain M.D.,
  Exec. VP, Chief Medical Officer & Exec. Employee Director
• Dr. Sangita Ghosh Ph.D.,
  Sr. VP of Technical Operations
• Dalia R. Rayes,
  Sr. VP & Head of Commercial
• Kari E. Leetch,
  Sr. VP of HR
• Tausif Butt,
  Exec. VP & COO
• Roger C Lucas,
  Director
• Petrus Bekker,
  SVP of Medical & Clinical
• Rajinder Singh,
  SVP, Research
• Partners L P/Ilbiotechnolog...,
  
• Jennifer Lyn Herron,
  Director
• Pui San Kwan,
  Principal Acctg Officer
• William Fairey,
  Chief Operating Officer
• Plc Gsk,
  10% owner
• Edward Penhoet,
  Director
• Ira Klein,
  Director
• Partners L P/Ilbiotechnolog...,
  
• Anne Marie Duliege,
  EVP, Chief of Strategic Dev.
• Israel Charo,
  SVP, Research
• Juan C. Jaen,
  SVP, Drug Discovery & CSO
• Tausif Butt,
  EVP, Chief Operating Officer
• Partners L P/Ilbvf Investme...,
  
• Corp /Mn/ Techne,
  10% owner
• Advisors Llcorbimed Capital...,
  
• Rishi Gupta,
  Director
• (International) Ltd Vifor P...,
  
• Yi Ching Yau,
  SVP, Finance & Acctg Officer
• David E. Wheadon,
  Director